Our finding that AMPK inhibition abolishes the RAF inhibitor–driven paradoxical activation of RAF–MEK–ERK signaling in Ras-mutated cancer cells and thus inhibits their overgrowth provides a potential combination therapy to control Ras mutation–driven cancers. This evidence concerns the gene PRKAA1 and cancer.